Mostrar el registro sencillo del ítem

dc.contributor.authorÁlvarez Mercado, Ana Isabel 
dc.contributor.authorGulfo, Jose
dc.contributor.authorRomero-Gómez, Manuel
dc.contributor.authorJiménez Castro, Mónica B.
dc.contributor.authorGracia-Sancho, Jordi
dc.contributor.authorCarmen, Peralta
dc.date.accessioned2026-01-21T11:06:12Z
dc.date.available2026-01-21T11:06:12Z
dc.date.issued2019-05
dc.identifier.citationPublished version: Álvarez Mercado, Ana Isabel et al. Use of steatotic grafts in liver transplantation: current status. Liver Transplantation. vol. 25, no. 5, 2019. doi:10.1002/lt.25430es_ES
dc.identifier.urihttps://hdl.handle.net/10481/110033
dc.descriptionThis article was supported by the Ministerio de Economía y Competitividad, Madrid, Spain (project grant SAF2015-64857-R); the Instituto de Salud Carlos III (FIS PI17/00012); the European Union (Fondos FEDER, “una manera de hacer Europa”); the Centres de Recerca de Catalunya Program/Generalitat de Catalunya; and the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (project grants 2017-SGR-551 & 2017-SGR-517), Barcelona, Spain. Network Center for Biomedical Research in Hepatic and Digestive Diseases is funded by the Instituto de Salud Carlos III.es_ES
dc.description.abstractIn the field of liver transplantation, the demand for adequate allografts greatly exceeds the supply. Therefore, expanding the donor pool to match the growing demand is mandatory. The present review summarizes current knowledge of the pathophysi- ology of ischemia/reperfusion injury in steatotic grafts, together with recent pharmacological approaches aimed at maximizing the utilization of these livers for transplantation. We also describe the preclinical models currently available to understand the molecular mechanisms controlling graft viability in this specific type of donor, critically discussing the heterogeneity in animal models, surgical methodology, and therapeutic interventions. This lack of common approaches and interventions makes it difficult to establish the pathways involved and the relevance of isolated discoveries, as well as their transferability to clinical practice. Finally, we discuss how new therapeutic strategies developed from experimental studies are promising but that further studies are warranted to translate them to the bedside.es_ES
dc.description.sponsorshipMinisterio de Economía y Competitividad, Madrid, Spain (SAF2015-64857-R)es_ES
dc.description.sponsorshipInstituto de Salud Carlos III (FIS PI17/00012)es_ES
dc.description.sponsorshipEuropean Union (Fondos FEDER, “una manera de hacer Europa”)es_ES
dc.description.sponsorshipCentres de Recerca de Catalunya Program/Generalitat de Catalunyaes_ES
dc.description.sponsorshipSecretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2017-SGR-551 & 2017-SGR-517), Barcelona, Spain.es_ES
dc.description.sponsorshipInstituto de Salud Carlos IIIes_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleUse of steatotic grafts in liver transplantation: current statuses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1002/lt.25430
dc.type.hasVersionAMes_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional